This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint. The...
The court's decision could pave the way for medical applications of psilocybin. The post Federal Appeals Court Pressures DEA to Justify Psilocybin’s...
Alabama Psychedelic Reform is Lagging Alabama is a historically conservative state with little participation in drug reform efforts. As a result, most...
This week three doctors reviewed the test results comparing the two options for treatment-resistant depression (TRD). Electroconvulsive therapy (ECT) is...
As the psychedelic movement transforms and develops into a new entity, there is bound to be internal conflict and opposition. The fight to include indigenous...
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
– European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated...
A federal appeals court panel has begun hearing arguments in a case involving a Seattle doctor who sued the U.S. Drug Enforcement Administration for...
Strengthens its Network of Psychedelic Care Infrastructure Beckley Waves, the first venture studio focused on building and investing companies in the...
In breaking news, Beckley Waves announces the acquisition of Nue Life. The post Breaking News: Beckley Waves Acquires Nue Life appeared first on Micro...